In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens
Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infe...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/12/10/1481 |
| _version_ | 1827721956073406464 |
|---|---|
| author | Lubna Razaq Fakhur Uddin Shahzad Ali Shah Muhammad Abbasi Muhammad Sohail Nabila E. Yousif Hala M. Abo-Dief Zeinhom M. El-Bahy |
| author_facet | Lubna Razaq Fakhur Uddin Shahzad Ali Shah Muhammad Abbasi Muhammad Sohail Nabila E. Yousif Hala M. Abo-Dief Zeinhom M. El-Bahy |
| author_sort | Lubna Razaq |
| collection | DOAJ |
| description | Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infections caused by drug-resistant pathogens. This study was designed to screen Enterobacteriales isolates from UTI patients and to assess their antimicrobial resistance pattern, particularly against the mentioned (new) antibiotics. Phenotypic screening of extended-spectrum β-lactamase (ESBL) and carbapenem resistance was followed by inhibitor-based assays to detect <i>K. pneumoniae</i> carbapenemase (KPC), metallo-β-lactamase (MBL), and class D oxacillinases (OXA). Among 289 Enterobacteriales, <i>E. coli</i> (66.4%) was the most predominant pathogen, followed by <i>K. pneumoniae</i> (13.8%) and <i>P. mirabilis</i> (8.3%). The isolates showed higher resistance to penicillins and cephalosporins (70–87%) than to non-β-lactam antimicrobials (33.2–41.5%). NDM production was a common feature among carbapenem-resistant (CR) isolates, followed by KPC and OXA. ESBL producers were susceptible to the tested new antibiotics, but NDM-positive isolates appeared resistant to these combinations. KPC-producers showed resistance to only C/T. ESBLs and carbapenemase encoding genes were located on plasmids and most of the genes were successfully transferred to recipient cells. This study revealed that MEV and CZA had significant activity against ESBL and KPC producers. |
| first_indexed | 2024-03-10T21:29:11Z |
| format | Article |
| id | doaj.art-365046029f0d46cb95c30876b642beca |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T21:29:11Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-365046029f0d46cb95c30876b642beca2023-11-19T15:26:05ZengMDPI AGAntibiotics2079-63822023-09-011210148110.3390/antibiotics12101481In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales UropathogensLubna Razaq0Fakhur Uddin1Shahzad Ali2Shah Muhammad Abbasi3Muhammad Sohail4Nabila E. Yousif5Hala M. Abo-Dief6Zeinhom M. El-Bahy7Department of Microbiology, University of Karachi, Karachi 75270, PakistanDepartment of Microbiology, Basic Medical Sciences Institute (BMSI), Jinnah Postgraduate Medical Center (JPMC), Karachi 75510, PakistanDepartment of Urology, Jinnah Postgraduate Medical Center (JPMC), Karachi 75510, PakistanDepartment of Main Clinical Laboratory, Jinnah Postgraduate Medical Center (JPMC), Karachi 75510, PakistanDepartment of Microbiology, University of Karachi, Karachi 75270, PakistanDepartment of Science and Technology, University College-Ranyah, Taif University, P.O. Box 11099, Taif 21944, Saudi ArabiaDepartment of Science and Technology, University College-Ranyah, Taif University, P.O. Box 11099, Taif 21944, Saudi ArabiaDepartment of Chemistry, Faculty of Science, Al-Azhar University, Cairo 11884, EgyptAntibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infections caused by drug-resistant pathogens. This study was designed to screen Enterobacteriales isolates from UTI patients and to assess their antimicrobial resistance pattern, particularly against the mentioned (new) antibiotics. Phenotypic screening of extended-spectrum β-lactamase (ESBL) and carbapenem resistance was followed by inhibitor-based assays to detect <i>K. pneumoniae</i> carbapenemase (KPC), metallo-β-lactamase (MBL), and class D oxacillinases (OXA). Among 289 Enterobacteriales, <i>E. coli</i> (66.4%) was the most predominant pathogen, followed by <i>K. pneumoniae</i> (13.8%) and <i>P. mirabilis</i> (8.3%). The isolates showed higher resistance to penicillins and cephalosporins (70–87%) than to non-β-lactam antimicrobials (33.2–41.5%). NDM production was a common feature among carbapenem-resistant (CR) isolates, followed by KPC and OXA. ESBL producers were susceptible to the tested new antibiotics, but NDM-positive isolates appeared resistant to these combinations. KPC-producers showed resistance to only C/T. ESBLs and carbapenemase encoding genes were located on plasmids and most of the genes were successfully transferred to recipient cells. This study revealed that MEV and CZA had significant activity against ESBL and KPC producers.https://www.mdpi.com/2079-6382/12/10/1481meropenem/vaborbactamceftazidime/avibactam<i>Klebsiella pneumoniae</i> carbapenemaseNew Delhi metallo-β-lactamase |
| spellingShingle | Lubna Razaq Fakhur Uddin Shahzad Ali Shah Muhammad Abbasi Muhammad Sohail Nabila E. Yousif Hala M. Abo-Dief Zeinhom M. El-Bahy In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens Antibiotics meropenem/vaborbactam ceftazidime/avibactam <i>Klebsiella pneumoniae</i> carbapenemase New Delhi metallo-β-lactamase |
| title | In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens |
| title_full | In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens |
| title_fullStr | In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens |
| title_full_unstemmed | In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens |
| title_short | In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens |
| title_sort | in vitro activity of new β lactamase inhibitor combinations against i bla i sub ndm sub i bla i sub kpc sub and esbl producing enterobacteriales uropathogens |
| topic | meropenem/vaborbactam ceftazidime/avibactam <i>Klebsiella pneumoniae</i> carbapenemase New Delhi metallo-β-lactamase |
| url | https://www.mdpi.com/2079-6382/12/10/1481 |
| work_keys_str_mv | AT lubnarazaq invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT fakhuruddin invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT shahzadali invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT shahmuhammadabbasi invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT muhammadsohail invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT nabilaeyousif invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT halamabodief invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens AT zeinhommelbahy invitroactivityofnewblactamaseinhibitorcombinationsagainstiblaisubndmsubiblaisubkpcsubandesblproducingenterobacterialesuropathogens |